![Leiden Dworak](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Leiden Dworak
Comptroller/Controller/Auditor chez TSCAN THERAPEUTICS, INC.
Fortune : 48 667 $ au 31/05/2024
Profil
Leiden Dworak is currently working as the Principal Accounting Officer at TScan Therapeutics, Inc. since 2023.
Previously, Leiden held the position of Director at Moderna, Inc. and VP, Head-Finance Planning & Analysis at Avrobio,.
Inc. Leiden completed an MBA from Indiana University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
TSCAN THERAPEUTICS, INC.
0,01% | 21/07/2023 | 5 692 ( 0,01% ) | 48 667 $ | 31/05/2024 |
Postes actifs de Leiden Dworak
Sociétés | Poste | Début |
---|---|---|
TSCAN THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 21/07/2023 |
Anciens postes connus de Leiden Dworak
Sociétés | Poste | Fin |
---|---|---|
MODERNA, INC. | Directeur/Membre du Conseil | - |
TECTONIC THERAPEUTIC, INC. | Corporate Officer/Principal | - |
Formation de Leiden Dworak
Indiana University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
TSCAN THERAPEUTICS, INC. | Health Technology |
MODERNA, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Avrobio, Inc.
![]() Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |